NDA 019268 · Pfizer
Cytotec
Misoprostol · Oral · Prostaglandin E1 Analog
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Feb 28, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1988
Dec 27, 1988
Approved uses
1
Original approval plus efficacy supplements
Registered trials
481
104 Phase 3, 18 recruiting
FAERS reports
9,774
6,754 serious, 746 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNINGS MISOPROSTOL ADMINISTRATION TO WOMEN WHO ARE PREGNANT CAN CAUSE BIRTH DEFECTS, ABORTION, PREMATURE BIRTH OR UTERINE RUPTURE. UTERINE RUPTURE HAS BEEN REPORTED WHEN MISOPROSTOL WAS ADMINISTERED IN PREGNANT WOMEN TO INDUCE LABOR OR TO INDUCE ABORTION. THE RISK OF UTERINE RUPTURE INCREASES WITH ADVANCING GESTATIONAL AGES AND WITH PRIOR UTERINE SURGERY, INCLUDING CESAREAN DELIVERY (see also PRECAUTIONS and LABOR AND DELIVERY ). MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). PATIENTS MUST BE ADVISED OF THE ABORTIFACIENT PROPERTY AND WARNED NOT TO GIVE THE DRUG TO OTHERS. Misoprostol should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from...
What it is approved for
From the label in effect Nov 4, 2026.
INDICATIONS AND USAGE Misoprostol is indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Misoprostol should be taken for the duration of NSAID therapy. Misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 27, 1988 Original approval · Type 1 - New Molecular Entity · priority review ReviewOther Important Information from FDA
2 products under this application
- CYTOTEC · MISOPROSTOL 0.1MG · TABLET, ORAL · Prescription · TE AB
- CYTOTEC · MISOPROSTOL 0.2MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Misoprostol" as an intervention, any sponsor and status, largest first.
Gynuity Health ProjectsAcademic, hospital or other
NCT02853552 · 4,330 participants (planned) · Start Oct 2016 · Primary completion Oct 2017
Drug: Misoprostol · For: Postpartum Hemorrhage
- Saving Lives at Birth in Uganda: Building and Sustaining Capacity of Frontline Health Workers - A Program EvaluationPivotal-lookingCompleted
JhpiegoAcademic, hospital or other
NCT03254628 · 3,440 participants · Start Nov 14, 2014 · Primary completion Dec 31, 2016
Drug: oxytocin and misoprostol · For: Postpartum Hemorrhage; Neonatal Asphyxia
- Misoprostol for Secondary Prevention of Postpartum Hemorrhage at the Community Level in IndiaPivotal-lookingCompleted
Gynuity Health ProjectsAcademic, hospital or other
NCT01462422 · 3,032 participants · Start Dec 2011 · Primary completion Mar 2014
Drug: Misoprostol; Misoprostol · For: Postpartum Hemorrhage
Sites: Vijayapura, India
- Comparison of Primary and Secondary Prevention of Postpartum Hemorrhage at the Community Level in EgyptPivotal-lookingCompleted
Gynuity Health ProjectsAcademic, hospital or other
NCT02226588 · 2,827 participants · Start Oct 2014 · Primary completion Jan 2016
Drug: Misoprostol · For: Postpartum Hemorrhage
Sites: Damanhur, Egypt; Kafr El Dawar, Egypt
- The Misoprostol-Only Regimen Evidence StudyPivotal-lookingNot yet recruiting
Ibis Reproductive HealthAcademic, hospital or other
NCT07174856 · 1,900 participants (planned) · Start Oct 10, 2025 · Primary completion Jan 2027
Drug: Misoprostol-only medication abortion regimen; Combined regimen · For: Abortion, Medical
Sites: Salt Lake City, Utah
- Misoprostol for the Treatment of Postpartum HemorrhagePivotal-lookingCompleted
Gynuity Health ProjectsAcademic, hospital or other
NCT00116350 · 1,786 participants · Start Jul 2005 · Primary completion Jan 2008
Drug: Misoprostol; Oxytocin · For: Postpartum Hemorrhage
Sites: Bobo Diolasso, Burkina Faso; Quito, Ecuador; Alexandria, Egypt · 6 sites in all
Gynuity Health ProjectsAcademic, hospital or other
NCT01798017 · 1,738 participants · Start Nov 2012 · Primary completion Jun 2015
Drug: Mifepristone and misoprostol · For: Menstrual Regulation
Sites: Aminbazar, Bangladesh; Savar Upazila, Bangladesh; Tetuljhora, Bangladesh · 8 sites in all
- Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum HaemorrhagePivotal-lookingTerminated
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01113229 · 1,721 participants · Start Mar 2010 · Primary completion Jul 2014
Drug: Misoprostol · For: Hemorrhage; Complicating Delivery
Sites: Poissy, France
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- haemorrhage1,260
- abortion incomplete1,159
- off label use924
- foetal exposure during pregnancy652
- pain542
- anaemia511
- pregnancy449
- nausea448
- drug ineffective442
- vomiting427
- maternal exposure during pregnancy420
- pyrexia408
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 503 |
| 2005 | 419 |
| 2006 | 388 |
| 2007 | 347 |
| 2008 | 346 |
| 2009 | 385 |
| 2010 | 553 |
| 2011 | 611 |
| 2012 | 621 |
| 2013 | 409 |
| 2014 | 402 |
| 2015 | 376 |
| 2016 | 403 |
| 2017 | 415 |
| 2018 | 372 |
| 2019 | 451 |
| 2020 | 719 |
| 2021 | 498 |
| 2022 | 402 |
| 2023 | 329 |
| 2024 | 289 |
| 2025 | 307 |
| 2026 | 227 |
Recalls
1 FDA enforcement reports for this application.
Sep 9, 2016 · Class III · Terminated
Failed Impurities/Degradations Specifications; Out of specification results for two known degradation products and total impurities at 18 months
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cytotec (Misoprostol)
2024 spending
$27K
Beneficiaries
n/a
20 claims
Per beneficiary
n/a
$5.44 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $35,953 |
| 2021 | $50,486 |
| 2022 | $41,251 |
| 2023 | $33,330 |
| 2024 | $26,860 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.
Gallos ID, Yunas I, Devall AJ, et al. · Cochrane Database Syst Rev 2025 · Network Meta-Analysis, Systematic Review
- Low-dose oral misoprostol for induction of labour.
Kerr RS, Kumar N, Williams MJ, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
- Administration of rectal cytotec versus rectal buscopan before hysteroscopy.
Gokmen Karasu AF, Aydin S, Ates S, et al. · Minim Invasive Ther Allied Technol 2022 · Randomized Controlled Trial
- Medical treatments for incomplete miscarriage.
Kim C, Barnard S, Neilson JP, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Treatment for primary postpartum haemorrhage.
Mousa HA, Blum J, Abou El Senoun G, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Medical treatments for incomplete miscarriage.
Neilson JP, Gyte GM, Hickey M, et al. · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.